| Literature DB >> 34909370 |
Percy Herrera-Añazco1,2,3, Diego Urrunaga-Pastor4, Vicente A Benites-Zapata3,5, Guido Bendezu-Quispe3,6, Carlos J Toro-Huamanchumo7,8, Adrian V Hernandez9,10.
Abstract
INTRODUCTION: Community mitigation strategies (CMS) have demonstrated to be effective in the reduction of transmission and incidence of COVID-19, especially in the population with symptoms associated with the disease. The aim of this study was to evaluate the association between the presence of COVID-19 symptoms and adherence to CMS in Latin American adults.Entities:
Keywords: COVID-19; Coronavirus infections; Hand disinfection; Latin America; Masks; Pandemics; Physical distancing; SARS-CoV-2; Social networking
Year: 2021 PMID: 34909370 PMCID: PMC8662838 DOI: 10.1016/j.pmedr.2021.101665
Source DB: PubMed Journal: Prev Med Rep ISSN: 2211-3355
Descriptive and bivariate analysis of the study sample characteristics according to COVID-19 symptoms (n = 1,310,690; N = 11,267,524).
| Total | Yes | No | ||||||
|---|---|---|---|---|---|---|---|---|
| Characteristics | Absolute frequency of participants surveyed | Weighted proportion according to each category | Weighted proportion according to each category | Weighted proportion according to each category | p value | |||
| N | % | 95%CI | % | 95%CI | % | 95%CI | ||
| Gender | <0.001 | |||||||
| Male | 580,426 | 48.1 | 47.7–48.5 | 40.2 | 39.4–41.0 | 49.9 | 49.5–50.3 | |
| Female | 715,989 | 50.5 | 50.1–50.9 | 58.4 | 57.6–59.2 | 48.7 | 48.3–49.1 | |
| No binary | 14,275 | 1.4 | 1.2–1.7 | 1.4 | 1.2–1.6 | 1.4 | 1.2–1.7 | |
| Age (years) | <0.001 | |||||||
| 18–24 | 310,465 | 18.1 | 17.4–18.8 | 27.2 | 26.3–28.3 | 16.0 | 15.3–16.7 | |
| 25–34 | 404,690 | 24.8 | 24.1–25.5 | 30.0 | 29.4–30.7 | 23.6 | 22.9–24.3 | |
| 35–44 | 277,273 | 18.7 | 18.4–19.0 | 18.3 | 17.7–18.8 | 18.8 | 18.5–19.1 | |
| 45–54 | 175,466 | 18.7 | 18.4–19.0 | 14.6 | 14.0–15.2 | 19.7 | 19.3–20.0 | |
| 55–64 | 102,144 | 11.1 | 10.7–11.5 | 6.1 | 5.7–6.5 | 12.3 | 11.8–12.7 | |
| 65–74 | 34,735 | 7.4 | 6.9–8.0 | 3.2 | 2.9–3.6 | 8.4 | 7.8–9.1 | |
| 75 years or older | 5,917 | 1.2 | 1.1–1.3 | 0.5 | 0.4–0.7 | 1.3 | 1.2–1.5 | |
| Area of residence | <0.001 | |||||||
| City | 1,030,744 | 78.9 | 75.7–81.8 | 81.8 | 78.6–84.6 | 78.3 | 75.1–81.1 | |
| Town | 182,088 | 13.8 | 11.5–16.5 | 12.2 | 9.9–15.0 | 14.2 | 11.9–16.9 | |
| Village or rural area | 97,858 | 7.3 | 6.6–8.0 | 6.0 | 5.4–6.6 | 7.5 | 6.8–8.3 | |
| Anxiety symptomatology | <0.001 | |||||||
| Yes | 625,860 | 44.7 | 44.0–45.3 | 65.6 | 65.0–66.3 | 39.9 | 39.3–40.5 | |
| No | 684,830 | 55.3 | 54.7–56.0 | 34.4 | 33.7–35.1 | 60.1 | 59.5–60.7 | |
| Depressive symptomatology | <0.001 | |||||||
| Yes | 663,934 | 46.6 | 45.9–47.4 | 68.7 | 68.0–69.5 | 41.6 | 40.8–42.4 | |
| No | 646,756 | 53.4 | 52.6–54.1 | 31.3 | 30.5–32.1 | 58.4 | 57.6–59.2 | |
| Level of CMS applied | <0.001 | |||||||
| Low | 315,823 | 20.1 | 11.9–32.0 | 20.7 | 12.1–33.1 | 20.0 | 11.9–31.8 | |
| Intermediate | 463,658 | 41.0 | 27.9–55.5 | 45.1 | 30.9–60.1 | 40.0 | 27.2–54.4 | |
| High | 531,209 | 38.9 | 28.5–50.4 | 34.2 | 24.3–45.7 | 40.0 | 29.5–51.4 | |
95%CI: 95% confidence intervals.
Bivariate analysis of the sample characteristics according to compliance with the principal community mitigation strategies in the study sample.
| Yes | No | ||||
|---|---|---|---|---|---|
| Characteristics | Weighted proportion according to each category | Weighted proportion according to each category | p value | ||
| % | 95%CI | % | 95%CI | ||
| Gender | <0.001 | ||||
| Male | 44.6 | 43.6–45.7 | 55.4 | 54.3–56.4 | |
| Female | 45.9 | 44.7–47.1 | 54.1 | 52.9–55.3 | |
| No binary | 43.5 | 40.7–46.3 | 56.5 | 53.7–59.3 | |
| Age (years) | <0.001 | ||||
| 18–24 | 37.4 | 36.0–38.9 | 62.6 | 61.1–64.0 | |
| 25–34 | 42.8 | 41.3–44.4 | 57.2 | 55.6–58.7 | |
| 35–44 | 47.2 | 45.7–48.7 | 52.8 | 51.3–54.3 | |
| 45–54 | 50.9 | 50.1–51.7 | 49.1 | 48.3–49.9 | |
| 55–64 | 50.4 | 49.4–51.4 | 49.6 | 48.6–50.6 | |
| 65–74 | 46.7 | 45.3–48.0 | 53.3 | 52.0–54.7 | |
| 75 years or older | 39.0 | 37.1–41.0 | 61.0 | 59.0–62.9 | |
| Area of residence | <0.001 | ||||
| City | 46.1 | 44.8–47.3 | 53.9 | 52.7–55.2 | |
| Town | 42.6 | 41.5–43.8 | 57.4 | 56.2–58.5 | |
| Village or rural area | 41.4 | 40.1–42.8 | 58.6 | 57.2–60.0 | |
| Anxiety symptomatology | 0.275 | ||||
| Yes | 45.0 | 43.5–46.5 | 55.0 | 53.5–56.5 | |
| No | 45.5 | 44.6–46.4 | 54.5 | 53.6–55.4 | |
| Depressive symptomatology | <0.001 | ||||
| Yes | 44.0 | 42.4–45.5 | 56.0 | 54.5–57.6 | |
| No | 46.4 | 45.6–47.2 | 53.6 | 52.8–54.4 | |
| COVID-19 symptomatology | <0.001 | ||||
| No | 46.7 | 45.7–47.7 | 53.3 | 52.3–54.3 | |
| Yes | 38.9 | 37.5–40.4 | 61.1 | 59.6–62.5 | |
| Level of CMS applied | 0.002 | ||||
| Low | 43.1 | 42.2–44.1 | 56.9 | 55.9–57.8 | |
| Intermediate | 44.4 | 42.5–46.4 | 55.6 | 53.6–57.5 | |
| High | 47.3 | 46.1–48.5 | 52.7 | 51.5–53.9 | |
95%CI: 95% confidence intervals.
Bivariate analysis of the study sample characteristics according to different community mitigation strategies (n = 1,310,690; N = 11,267,524).
| Yes | No | No | Yes | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Characteristics | Weighted proportion according to each category | Weighted proportion according to each category | p value | Weighted proportion according to each category | Weighted proportion according to each category | p value | Weighted proportion according to each category | Weighted proportion according to each category | p value | ||||||
| % | 95%CI | % | 95%CI | % | 95%CI | % | 95%CI | % | 95%CI | % | 95%CI | ||||
| Gender | <0.001 | <0.001 | <0.001 | ||||||||||||
| Male | 55.7 | 54.4–57.0 | 44.3 | 43.0–45.6 | 89.9 | 88.9–90.9 | 10.1 | 9.1–11.1 | 86.2 | 84.4–87.7 | 13.8 | 12.3–15.6 | |||
| Female | 63.1 | 61.6–64.7 | 36.9 | 35.3–38.4 | 83.6 | 82.4–84.8 | 16.4 | 15.2–17.6 | 80.1 | 78.5–81.6 | 19.9 | 18.4–21.5 | |||
| No binary | 66.7 | 63.1–70.0 | 33.3 | 30.0–36.9 | 78.4 | 75.8–80.7 | 21.6 | 19.3–24.2 | 72.8 | 69.2–76.1 | 27.2 | 23.9–30.8 | |||
| Age (years) | <0.001 | <0.001 | <0.001 | ||||||||||||
| 18–24 | 53.5 | 51.7–55.3 | 46.5 | 44.7–48.3 | 84.5 | 83.3–85.5 | 15.5 | 14.5–16.7 | 78.4 | 76.3–80.4 | 21.6 | 19.6–23.7 | |||
| 25–34 | 54.1 | 52.5–55.7 | 45.9 | 44.3–47.5 | 89.7 | 88.9–90.4 | 10.3 | 9.6–11.1 | 85.6 | 83.6–87.4 | 14.4 | 12.6–16.4 | |||
| 35–44 | 58 | 56.1–59.9 | 42 | 40.1–43.9 | 90.2 | 89.2–91.1 | 9.8 | 8.9–10.8 | 87.2 | 85.5–88.7 | 12.8 | 11.3–14.5 | |||
| 45–54 | 63.4 | 62.0–64.8 | 36.6 | 35.2–38.0 | 88.5 | 87.1–89.7 | 11.5 | 10.3–12.9 | 86.0 | 84.5–87.4 | 14.0 | 12.6–15.5 | |||
| 55–64 | 67.8 | 66.5–69.1 | 32.2 | 30.9–33.5 | 83.6 | 81.8–85.4 | 16.4 | 14.6–18.2 | 81.4 | 79.7–82.9 | 18.6 | 17.1–20.3 | |||
| 65–74 | 72.9 | 71.8–74.0 | 27.1 | 26.0–28.2 | 75.1 | 73.3–76.8 | 24.9 | 23.2–26.7 | 72.1 | 70.1–74.0 | 27.9 | 26.0–29.9 | |||
| 75 years or older | 73.8 | 71.3–76.1 | 26.2 | 23.9–28.7 | 65.5 | 62.9–67.9 | 34.5 | 32.1–37.1 | 60.2 | 58.0–62.4 | 39.8 | 37.6–42.0 | |||
| Area of residence | <0.001 | <0.001 | <0.001 | ||||||||||||
| City | 59.3 | 57.7–60.9 | 40.7 | 39.1–42.3 | 87.6 | 86.5–88.6 | 12.4 | 11.4–13.5 | 84.3 | 82.5–86.0 | 15.7 | 14.0–17.5 | |||
| Town | 59.4 | 58.3–60.5 | 40.6 | 39.5–41.7 | 84.3 | 83.7–84.9 | 15.7 | 15.1–16.3 | 79.5 | 77.7–81.2 | 20.5 | 18.8–22.3 | |||
| Village or rural area | 63.4 | 62.0–64.8 | 36.6 | 35.2–38.0 | 79.9 | 78.8–81.0 | 20.1 | 19.0–21.2 | 73.7 | 71.4–75.9 | 26.3 | 24.1–28.6 | |||
| Anxiety symptomatology | <0.001 | <0.001 | <0.001 | ||||||||||||
| Yes | 57.7 | 55.9–59.4 | 42.3 | 40.6–44.1 | 88 | 87.0–88.9 | 12 | 11.1–13.0 | 84.6 | 82.9–86.1 | 15.4 | 13.9–17.1 | |||
| No | 61.1 | 60.0–62.4 | 38.8 | 37.6–40.0 | 85.4 | 84.2–86.6 | 14.6 | 13.4–15.8 | 81.6 | 79.8–83.2 | 18.4 | 16.8–20.2 | |||
| Depressive symptomatology | <0.001 | <0.001 | <0.001 | ||||||||||||
| Yes | 57.2 | 55.5–58.9 | 42.8 | 41.1–44.5 | 87.4 | 86.4–88.3 | 12.6 | 11.7–13.5 | 83.7 | 82.0–85.4 | 16.3 | 14.6–18.0 | |||
| No | 61.7 | 60.5–62.9 | 38.3 | 37.1–39.5 | 85.9 | 84.6–87.1 | 14.1 | 12.9–15.4 | 82.2 | 80.5–83.8 | 17.8 | 16.2–19.5 | |||
| COVID-19 symptomatology | <0.001 | <0.001 | <0.001 | ||||||||||||
| No | 62.0 | 60.6–63.3 | 38.0 | 36.7–39.4 | 85.9 | 84.7–87.0 | 14.1 | 13.0–15.3 | 82.4 | 80.7–83.9 | 17.6 | 16.1–19.3 | |||
| Yes | 49.3 | 47.8–50.8 | 50.7 | 49.2–52.2 | 89.6 | 88.8–90.4 | 10.4 | 9.6–11.2 | 85.3 | 83.1–87.2 | 14.7 | 12.8–16.9 | |||
| Level of CMS applied | <0.001 | <0.001 | <0.001 | ||||||||||||
| Low | 58.5 | 56.0–60.9 | 41.5 | 39.1–44.0 | 86.5 | 86.0–87.0 | 13.5 | 13.0–14.0 | 80.7 | 78.1–83.1 | 19.3 | 16.9–21.9 | |||
| Intermediate | 55.5 | 54.2–56.7 | 44.5 | 43.3–45.8 | 90.8 | 90.2–91.4 | 9.2 | 8.6–9.8 | 85.4 | 80.9–89.0 | 14.6 | 11.0–19.1 | |||
| High | 64.6 | 63.3–65.9 | 35.4 | 34.1–36.7 | 82.2 | 81.5–82.9 | 17.8 | 17.1–18.5 | 81.4 | 80.4–82.3 | 18.6 | 17.7–19.6 | |||
95%CI: 95% confidence intervals.
Fig. 1Prevalence of compliance with community mitigation strategies according to each country in Latin America. A: Compliance with the three principal community mitigation strategies; B: Compliance with physical distancing; C: Compliance with hand washing; C: Compliance with the use of a mask.
Fig. 2Prevalence of compliance with secondary outcomes according to each country in Latin America. A: Compliance with isolation due to contact with a respiratory symptomatic; B: Compliance with isolation due to being symptomatic.
Generalized linear models of the Poisson family to evaluate the association between COVID-19 symptoms and compliance with community mitigation strategies in the study sample.
| Crude | Adjusted | |||||
|---|---|---|---|---|---|---|
| COVID-19 symptomatology | cPR | 95%CI | p value | aPR* | 95%CI | p value |
| No | Reference | – | – | Reference | – | – |
| Yes | 0.83 | 0.82–0.85 | <0.001 | 0.86 | 0.85–0.87 | <0.001 |
| COVID-19 symptomatology | ||||||
| No | Reference | – | – | Reference | – | – |
| Yes | 0.80 | 0.78–0.81 | <0.001 | 0.83 | 0.82–0.84 | <0.001 |
| COVID-19 symptomatology | ||||||
| No | Reference | – | – | Reference | – | – |
| Yes | 1.04 | 1.04–1.05 | <0.001 | 1.03 | 1.02–1.04 | <0.001 |
| COVID-19 symptomatology | ||||||
| No | Reference | – | – | Reference | – | – |
| Yes | 1.04 | 1.03–1.05 | <0.001 | 1.03 | 1.02–1.03 | <0.001 |
| COVID-19 symptomatology | ||||||
| No | Reference | – | – | Reference | – | – |
| Yes | 1.08 | 1.01–1.17 | 0.035 | 1.05 | 0.98–1.14 | 0.186 |
95%CI: 95% confidence intervals; cPR: Crude prevalence ratio; aPR: Adjusted prevalence ratio.
*Adjusted for: gender, age, area of residence, anxiety, depression symptomatology and level of CMS applied.